Reaction

Vanishing Bile Duct Syndrome reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,096 reports · 54 co-occurring drugs

As of the last recalculation, Vanishing Bile Duct Syndrome appears in 1,096 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is NEVIRAPINE (PRR 94.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Nevirapine	43	94.2	94.6
Daspone	28	56.0	56.2
Dapsone Gel, 5%	28	56.0	56.1
Temozolomide	57	54.1	54.3
Ursosiol	50	51.1	51.3
Dapsone	28	51.1	51.2
Efavirenz	28	48.9	49.0
Ursodiol	50	45.6	45.7
Minocycline	19	31.5	31.5
Tenofovir Disoproxil Fumarate Tablets	14	31.2	31.2
Lamivudine Oral	39	30.3	30.4
Loperamide Hcl	18	27.0	27.0
Drs. Clotrimazole	16	26.7	26.7
Family Wellness Clotrimazole	16	26.7	26.7
Clotrimazole Topical	16	26.7	26.7
Clotrimazole	16	25.1	25.1
Lamivudine	39	24.8	24.8
Thiotepa	12	24.1	24.1
Lacosamide	45	23.9	23.9
Atazanavir	17	22.8	22.8
Ceftriaxone	37	22.1	22.2
Ritonavir 100 Mg	17	21.9	22.0
Moxifloxacin	15	20.5	20.5
Basiliximab	12	19.6	19.6
Ceftriaxone Sodium	38	19.5	19.5
Loperamide Hydrochloride Oral	10	18.8	18.8
Zidovudine	13	18.7	18.7
Bleomycin Sulfate	10	18.5	18.6
Zonisamide	14	18.2	18.2
Metronidazole Topical	43	17.8	17.8
Metronidazole	55	17.2	17.2
Ciprofolxacin	61	17.1	17.1
Ciprofloxacin Tablets	61	17.1	17.1
Clarithromycin	29	16.4	16.5
Meropenem	26	15.7	15.7
Rifampicin	8	15.1	15.1
Azithromycin	31	15.0	15.0
Busulfan	12	14.6	14.6
Azithromycin Monohydrate	31	14.5	14.5
Piperacillin Sodium,Tazobactam Sodium	19	13.8	13.8
Amphotericin B	9	13.7	13.8
Cefepime	10	13.4	13.4
Cefepime Hydrochloride	11	13.1	13.1
Levetiracetam In Sodium Chloride	50	12.8	12.8
Levetiracetam Oral	50	12.8	12.8
Levetiracetam Injection	50	12.8	12.8
Ritonavir	17	11.2	11.2
Tenofovir Disoproxil Fumarate	17	9.9	9.9
Pemetrexed	10	8.9	8.9
Suvorexant	5	7.4	7.4
Pembrolizumab	39	7.3	7.3
Minoxidil Foam 5% (Womens)	10	5.8	5.8
Orlistat	6	4.4	4.4
Minoxidil	10	4.3	4.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.